Article thumbnail

Etanercept Treatment in Children With New-Onset Type 1 Diabetes: Pilot randomized, placebo-controlled, double-blind study

By Lucy Mastrandrea, Jihnhee Yu, Torsten Behrens, John Buchlis, Christine Albini, Shannon Fourtner and Teresa Quattrin
Topics: Original Research
Publisher: American Diabetes Association
OAI identifier: oai:pubmedcentral.nih.gov:2699714
Provided by: PubMed Central

Suggested articles

Citations

  1. A mouse CD8 T cell-mediated acute autoimmune diabetes independent of the perforin and Fas cytotoxic pathways:
  2. (2007). A placebocontrolled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology
  3. A single course of anti-CD3 monoclonal antibody hOKT31(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
  4. (1989). Adjustment to diabetes mellitus in preschoolers and their mothers. Diabetes Care
  5. (1994). Cytokines and diabetes: the final step?
  6. Cytokines in sera from insulin-dependent diabetic patients at diagnosis. Clin Exp Immunol 1991;86:
  7. Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis.
  8. (1988). Destruction of rat islet cell monolayers by cytokines: synergistic interactions of interferon-, tumor necrosis factor, lymphotoxin, and interleukin 1. Diabetes
  9. (1993). Dinarello CA,NerupJ.Involvementofinterleukin1 and interleukin 1 antagonist in pancreatic -cell destruction in insulin-dependent diabetes mellitus.
  10. (2005). Disease Control and Prevention. National Diabetes Fact Sheet.
  11. Effects of cytokines on rat pancreatic islet cell monolayer cultures: distinction between functional and cytotoxiceffectsonislet-cells.RegImmunol 1989;2:77–82
  12. Genes encoding tumor necrosis factor and granzyme A are expressedduringdevelopmentofautoimmune diabetes.
  13. (2009). GraningerW,WascherTC.Improvement of insulin sensitivity in insulin resistant subjectsduringprolongedtreatmentwith the anti-TNF- antibody infliximab.
  14. Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic -cell cytotoxicity.
  15. IFN- and tumor necrosis factor-: cytotoxicity to murine islets of Langerhans.
  16. (2007). Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology
  17. Interleukin-1 induced impairment in pancreatic islet oxidative metabolism of glucose is potentiated by tumor necrosis factor. Acta Endocrinol (Copenh)
  18. (2003). Pharmaceutical Statistics: Practical and Clinical Applications.
  19. (1989). Stress in parents of children with diabetes mellitus. Diabetes Care
  20. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
  21. Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascularriskfactors.JInternMed2000;

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.